All careers have twists and turns, going from one inclination to another. Mine was no exception but had a thread of urogynecology, beginning during my residency in obstetrics and gynecology, and then became full time during my sabbatical in 1975-and persists to this day. I started with a strong interest in oncologic surgery and was coauthor on the original manuscript on the use of cryosurgery in the treatment of cervical intraepithelial neoplasia, after we had described its facility in benign disease of the cervix. The development of a training program for women's health care nurse practitioners and physician's assistants emerged at the same time. When the oncology subspecialty board was established, I decided not to pursue that career. At that time, a former American College of Obstetrics and Gynecology (ACOG) president was asked to establish a subspecialty board in female incontinence, but he declined stating that it was not a big enough field.
As some of you may know, I am not a stranger to controversy. We were having such good luck with training women's health care specialists that it resulted in a presentation at an annual planned parenthood meeting in the early 1970s. It was received with a great deal of skepticism with statements such as, "My patients will never let a nurse take care of them, they can never substitute for physicians in any way and certainly will never be able to prescribe medications." Vindication seems to have arrived! When I was a second year resident at Harbor General Hospital which is now the Harbor/UCLA Medical Center in Torrance, CA, Dr. Jack Robertson drove down from Santa Ynez, CA (a 3-h drive north of Torrance) near where his private practice was located. One day, he was late because he had hit a deer in the mountains above Santa Barbara. He had a new idea, and a new instrument, which allowed the direct visualization of the female urethra for anatomical changes. It also allowed the introduction of carbon dioxide gas to record a cystometrogram. A female urology clinic resulted in 1965, where he taught us how to use his invention to evaluate our incontinent patients using a Heyer-Schulte recording cystometer. After I had enough time in place in academia to do a sabbatical, I chose to pursue the unknown field of female urology and visited several centers that were doing cutting edge clinical work in this discipline at that time, both in the US and abroad. In Oslo, Drs. Torkel Rud and Mogens Ausmussen were developing the microtransducer catheter; in London, Mr. Stuart Stanton was one of the first to use video urodynamics; and in San Francisco, Dr. Emil Tanagho had developed balloon catheters for use in urodynamics. Additionally, an intensive review of the virtually nonexistent medical literature was undertaken. At that time, there was no such thing as a urodynamic machine, but Dr. Tanagho modified a nearly 6-ft tall and 3-ft wide Beckman physiological recorder using ink pens to do the job, along with his double balloon catheters. Microtransducer catheters were only used in Europe at that time. We duplicated this urodynamic system and settled on the use of microtransducer catheters and became the first center in the US to use them when we opened our female urology clinic in 1977. The first fellow in the US (Dr. Tom McCarthy, deceased), began his training with me in 1978. During that same year, a postgraduate course was given in Los Angeles with more than 150 physicians from all over the world attending.
A short time earlier, the International Continence Society (ICS) was formed with only about 50 members. In 1976, Dr. Axel Ingelman-Sundberg called for an organizational meeting, which I attended, for the founding of the International Urogynecological Association (IUGA). A group of five of us formed the American Urogynecologic Society (AUGS) in 1979-then known as the Gynecologic Urology Society in an attempt to involve the urologists. The society had its first meeting in 1980 in New Orleans with Dr. Jack Robertson as its first president and I was the secretary-treasurer. The first textbook in the field was published in 1980, which was a compilation of lectures given at our postgraduate courses.
During my tenure as president of AUGS, an interesting situation developed with very tense relations between urologists and urogynecologists. There were high level discussions between the specialties at that time, and the president of ACOG attended our annual meeting to discuss this issue. Gynecologists were not allowed to perform cystoscopy in the operating room, and many of us wrote numerous letters in support of individual gynecologists to do this procedure, based on experience with Dr. Robertson's technique in their offices. The camaraderie between the specialties which we now enjoy is a welcome benefit that we all take for granted and which I am sure will continue with the recent formal establishment and national approval of a multidisciplinary subspecialty board.
Controversy struck me again when asked to give a talk on surgery for urinary incontinence at the New York Obstetrical Society in the early 1980s. When this group heard that anterior vaginal repairs with the Kelly-Kennedy suburethral plication only had a success rate of about 50% in curing stress incontinence, and that the Burch procedure had a much better cure rate, pandemonium broke out. The members related their clinical impressions that all their patients were cured and stated their disbelief in what I had said, even though this was validated by several published papers. None could actually relate that they had followed their patients carefully, and none could produce data. The suggestion was then made to follow-up their last 50 patients and actually determine how well they were doing. Actual data were never related to me. Again, I feel validated.
Ten years later, Dr. Oscar Contreras Ortiz of Argentina published the first issues of what he envisioned as an international urogynecology journal. He and I collaborated on this effort, securing a publisher (Springer-Verlag) with the resulting International Urogynecology Journal (IUJ). During my tenure as managing editor, it quickly became a daunting task with upwards of 4 h a day devoted to manuscript review, selecting and getting reviewers to comment, and the laborious task of translating English to English for those whose primary language was not English. All of this occurring without the aid of a computer or the Internet! Given that the journal is now in its 22nd volume, it is clear that the time spent was well worth the effort, and I am delighted with the progress of the IUJ under its subsequent leadership.
It has been very gratifying to observe the subspecialty grow at such a tremendous rate. Similarly, the scientific content of the AUGS annual meetings has been amazing when compared to the early meetings of some 30 years ago. IUGA has enjoyed similar progress on an international level with the joint meeting with the ICS setting a new record for attendance in Toronto last year. Given that AUGS started with about 60 members and the ICS with about 30, the progress and interest in the subspecialty has been phenomenal and well beyond my expectations.
Controversy is now rampant in the polymer mesh field. I have had concerns about this from the beginning, having had prior experience using such prostheses for stress incontinence with a 21% vaginal erosion rate and abscesses being found upwards of 5 years later. Resected specimens revealed the presence of marked bacterial colonization [1] . When surgical procedures for pelvic prolapse repair were first introduced, I warned against them. When the first kit containing mesh was offered for sale, disaster ensued. Prote-Gen® (Microvasive Urology) was ultimately removed from the market because of many erosions and urethrovaginal fistulae. The US Food and Drug Administration (FDA) ruled that the product was adulterated and misbranded and agreed with the recall. Interestingly, I was asked to review the data for this product before it was offered for sale by a venture capital company. The data were weak, and I advised against their financial involvement in what was to be the first incontinence surgical procedure for sale. Microvasive certainly did the right thing in recalling the product. The mesh used was polyestercoated with "pressure-injected" bovine collagen.
The FDA clears products by the 510k process. This process involves a predicate that must be similar to the same planned usage and technological characteristics as the new product. The TVT® used Prote-Gen® as its predicate, even though it is a polypropylene mesh product and not polyester with a bovine collagen coating. All of the currently marketed mesh kits are descendants of this adulterated product.
When Dr. Joe Montella, as AUGS president, asked me to give the J. Marion Sims Lecture in 2006, my topic was meshes as treatment for incontinence and prolapse. I think that most of the attendees' eyes glazed over during this presentation, who did not want to hear what was being said about the looming mesh problem. Afterwards, a few of the members voiced similar concerns regarding mesh usage, but probably the majority of members were opposed to the idea that meshes could be dangerous. As of now, there is partial vindication in the form of the FDA's warning in 2008 regarding mesh use in pelvic prolapse surgery, and more information is accumulating. Since 2006, the French health care system will not pay for a mesh to be used in prolapse repair unless the surgery is part of a clinical study [2] . Currently, there are four published papers of prospective, randomized clinical trials comparing mesh use with native tissue repairs in the anterior vaginal compartment. Each of these studies indicates that, although mesh yields better anatomical results, the patients do not perceive a benefit from its use since equal numbers in each group indicate similar improvement. There are six other studies in abstract form giving the same results. A recent paper showed the same responses in a group of patients undergoing recurrent anterior vaginal wall prolapse surgery [3] .
We now have evidence-based medicine which does not support the use of mesh for prolapse surgery in the anterior vaginal compartment when done vaginally. This begs the question, "What are we going to do with this data?" Mesh use certainly has utility for mid-urethral slings and abdominal sacral colpopexy, as the risk of mesh complications is low in these procedures. The search for the perfect mesh has eluded us to date. Perhaps there should be a place reserved at the Chicago Lying-in Hospital for the individual who describes the perfect mesh next to the site reserved for the physician who discovers the cause and cure for preeclampsia.
For me, full retirement from urogynecology is not going to happen anytime soon. As a "grand-fellow" of Dr. Don Ostergard, it gives me great pleasure to contribute to this publication. Hands down, the field of female pelvic medicine and reconstructive surgery would not exist as we know it today if it weren't for his vision, diligence, and perseverance.
I personally would not have entered into this field if I had not attended a grand rounds lecture that Don gave to our department in the last year of my residency. Thanks to a series of serendipitous events, I was able to train with one of Don's first fellows, Dr. Narrender Bhatia. Personally, I will always be indebted to Don for giving me the opportunity to become the Editor-In-Chief of the International Urogynecology Journal (IUJ). While this position contributed significantly to my academic career, it also allowed me the opportunity to interact with an international group of urogynecologists who will remain as friends and colleagues for the rest of my life.
As Don will soon be moving to Louisville, Kentucky, which is a short drive from Cincinnati, it will be an honor and pleasure to hopefully have the opportunity to interact with him on a regular basis.
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